DRAVP ID  DRAVPe02316

Peptide Name   EBOV-5

Sequence  DWTKNIKDKIDKIIHDFVDKTLPDQG

Sequence Length  26

UniProt ID  No entry found

Taxon ID  None

Source  Cholesterol-conjugated synthetic peptide

Validation   Experimentally Validated

Gene Name/ID  Not Available

GenBank  Not Available

Amino Acid position  Not Available

Domain Accession ID  Not Available

Nucleotide sequence ID  Not Available

Molecular Type  Not Available

Chromosomal Position  Not Available

Target Organism  EBOV

Assay  N/A

Activity 

• [Ref:31473342]EBOV:EC₅₀= 3.88 ± 0.67 μM, 3.89 ± 0.61 μM; EBOV EC₉₀=17.27 μM, 16.86 μM; EBOV-GP EC₅₀=2.45 ± 1.09 μM; EBOV-GP EC₉₀= 29.46 μM; ma-EBOV EC₅₀= 2.34 ± 0.69 μM; ma-EBOV EC₉₀=16.2 μM

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity 

• [Ref:31473342}EBOV:CC₅₀ > 30 μM; EBOV-5 CC₅₀ ≥ 25 μM (EBOV-GP); EBOV-5 CC₅₀ ≥ 51.7 μM (ma-EBOV).

Binding Target  Glycoprotein.

Mechanism  Exact MoA explicitly not available (may interfere with the binding of the Ebola virus glycoprotein to host cell receptors, thereby preventing viral entry into host cells).

PDB ID  None

Predicted Structure Download 

Linear/Cyclic  Cyclic

N-terminal Modification  cholesterylation

C-terminal Modification  PEG4

Other Modification  In the peptide sequence, the cysteine residue at position 27 is modified with a PEG4-cholesterol (PEG4-Chol) moiety.)

Stereochemistry  L

Literature 1

Title   Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo

Pubmed ID   31473342

Reference   Antiviral Res. 2019;171:104592. 

Author   Pessi A, Bixler SL, Soloveva V, et al

DOI   10.1016/j.antiviral.2019.104592